‘Dangerous Matter’: A New Opera on Vaccine Science, Memory, and Innovation
23 May 2025
The Thanks for the Memories public engagement programme are delighted to announce the next major event of their project: the premier of a new opera, ‘Dangerous Matter’, at the Royal Northern College of Music on June 24th, 2025, inspired by the story of Lady Mary Wortley Montagu and University of Oxford research into immune memory.
Coeliac disease may be driven by immune structures in the gut
7 May 2025
Researchers in the Nuffield Department of Medicine have found structures of immune cells in the gut that may be driving the response to gluten in people with coeliac disease. These findings could provide a target for future therapies.
TCRs drive CARs
1 May 2025
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between cancerous and healthy tissues—addressing a major challenge in current immunotherapy.
New episode of To Immunity and Beyond: Research with Human Tissue Samples on the International Space Station
1 May 2025
Ghada Alsaleh explains how research on human cells in space may uncover the hidden mechanisms behind ageing.
New Study Finds Common Virus May Improve Skin Cancer Treatment Outcomes
23 April 2025
A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
Sooraj Achar wins the 2025 Peter Medawar Prize for Immunology
16 April 2025
The 2025 prize was awarded to Sooraj Achar (NCI/Kennedy Institute) for his outstanding contribution to understanding T cell antigen recognition, particularly in the context of cancer immunotherapy, and wider contributions to the immunology community.
New episode of To Immunity and Beyond: Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype
27 March 2025
Dr Kirsty McHugh and Dr Carolyn Nielsen discuss a recent Cell article: ‘Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype’.
Oxford launches first human trial of aerosol vaccine delivery
27 March 2025
The University of Oxford in partnership with the Coler Lab at Seattle Children’s Research Institute (SCRI) has begun a new clinical trial called TB045, which aims to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-human aerosol mycobacterial challenge infection model with healthy adult volunteers.
Lower-dose yellow fever vaccine as effective as the current standard
20 March 2025
In a recent study, researchers at the KEMRI Wellcome Trust Research Programme in Kenya have discovered that a low-dose of the yellow fever vaccine is as effective as the current standard dose.
Immune response may be harnessed to control HIV
11 March 2025
Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.
Researchers receive funding to develop new therapies for drug-resistant tuberculosis
25 February 2025
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded £5 million to a group of interdisciplinary researchers from NDM and other departments at the University, to develop new therapies for drug-resistant tuberculosis.
Bangladesh malaria vaccine and drug administration trial begins
24 February 2025
After more than a year of community engagement and preparation in 100 villages with over 12,000 inhabitants across the Chittagong Hill Tracts, a mass malaria vaccine (R21/Matrix M) and drug administration (DHA, piperaquine, and single low dose primaquine) study was launched on 15 February.
Pancreatic cancer immune map provides clues for precision treatment targeting
7 February 2025
Study shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
Oxford and GSK launch £50m programme to advance cancer research
27 January 2025
Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.
BSI Oxford Immunology Symposium 2025
13 January 2025
New blood test could enable early detection of multiple cancers
8 January 2025
A new blood test – powered by machine learning – has shown real promise in detecting multiple types of cancer in their earliest stages, when the disease is hardest to detect. Developed by a team of researchers and co-lead by the Centre for Human Genetics’ Dr Dimitris Vavoulis, the test accurately detected six cancer types and could distinguish between people with and without cancer.
Reversing resistance to cancer immune therapy with antibodies
16 December 2024
A new study led by Professor Ignacio Melero of NDM's Centre for Immuno-oncology and the University of Navarra and has highlighted a way to combat resistance to cancer immunotherapy in solid tumours by using antibodies that target GDF-15 protein.